All News

Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR26 annual meeting is sponsored by Eli Lilly and Company. All coverage content is independently selected by RheumNow and its faculty.
Janet Pope Tweet
Janetbirdope
‘Strong’ data in #myositis #0904 #Efgartigimod ⬇️Igs &#Abs LB +ph3 #RCT -👍on Wed #0905 #nipocalimab in #IIM also #FcRn #0906 #ruxolitinib ⬆️#survival in severe #MDA5 - but not RCT #0907 +RCT IIM #Brepocitinib ☑️clinical remission ☑️HAQ ☑️LDA #ACR26 #ACRbest @RheumNow
anita Tweet
docdhanrajani
@RheumNow Building bridges to better care: Advocacy and legislative updates in pediatrics #ACR2026 The AAP advocates for equitable access to care, science-based policies, fair reimbursement & pediatric workforce equity. Advocacy is stronger together!
Daric Mueller, PA-C Tweet
rheumPAC
Mortality in IIM-ILD: frontloaded but survival + improvement possible! 2 year mortality outcomes in a newly diagnosed IIM-cohort (n=41), 15% died @ median time of 8.5 months. Of survivors, only 13.3% progressed, 46.7% improved as measured by % pred FVC. #ACR26 @Rheumnow
Antoni Chan MD (Prof) Tweet
synovialjoints
Five AI platforms were tested on 60 ACR and EULAR based scenarios: guideline concordance ranged from 74.9% to 91.2% and hallucination rates from 3.8% to 18.1%. Key finding: clinically relevant errors occurred on every platform, and the authors recommend clinician oversight.
Adela Castro Tweet
AdelaCastro222
Drug survival in axSpA: 22 years of real-world data: 431 axSpA patients received ≥1 b/tsDMARD. 74.0% stayed on a single therapy. 19.0% used 2, 6.0% used 3, and 0.9% used 4. -TNFi were the backbone: Adalimumab (mean 1,620 days) had longest persistence and still the dominant
Richard Conway Tweet
RichardPAConway
Rawas et al. Obinutuzimab in AAV. Effective, including in refractory and rituximab intolerant disease. BUT Infectious events in 46%, 6 hospitalised, 1 death. @RheumNow #ACR26 Abstr#0199
Dr. John Cush Tweet
RheumNow
Ode to Our Editor: Honoring Dr. Jack Cush This article comes as a surprise to its subject, our own founding editor, Dr. Jack Cush. His colleagues thought it was time he received a little recognition of his own. For someone who has spent so much of his career recognizing the https://t.co/fIBkMmEQju
Dr. John Cush Tweet
RheumNow
RheumNow’s expanded coverage of the #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb and Tonix. All coverage content is independently selected by RheumNow and its faculty.
×